INBX
Inhibrx Biosciences, Inc.Company with tickers: INBX
CIK
2007919
CUSIP
45720N103
Shares Outstanding
14,671,186
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $42,901,000 | USD | 2025-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $36,877,000 | USD | 2025-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-30,927,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-43,311,000 | USD | 2025-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-2.80 | USD/shares | 2025-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-2.80 | USD/shares | 2025-03-31 | 10-Q | 2026-05-14 |